We are a Phase 3 clinical stage biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics in immune disease. Our lead asset, RPC1063, is being developed as an oral therapy for Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD). The goal of our development strategy for RPC1063 is to demonstrate clinically meaningful differentiation versus other available treatments, including a favorable safety profile.
Meet the team »
We are currently enrolling the Phase 3 and 2 portions of an accelerated Phase 2/3 study of RPC1063 in RMS. More information about RADIANCE enrolling locations and patient eligibility requirements can be found here.
We are currently enrolling the Phase 2 study of RCP1063 in Ulcerative Colitis. More information about TOUCHSTONE enrolling locations and patient eligibility requirements can be found here.
July 29, 2014
Receptos Announces Appointment of Mary Szela and Richard Heyman, Ph.D. to Board of Directors… MORE »
June 24, 2014
Receptos Announces Closing of Underwritten Public Offering of Common Stock… MORE »
June 18, 2014
Receptos Announces Pricing of Underwritten Public Offering of Common Stock… MORE »
June 17, 2014
Receptos Announces Proposed Underwritten Public Offering of Common Stock… MORE »